Pretreatment brain states identify likely nonresponse to standard treatments for depression.

ABSTRACT:

Background

Treatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment. Added treatment generally improves remission rates, but approximately one third of all patients fail to respond after several treatments (sequential monotherapies or combined treatment). A pretreatment biomarker could help identify these patients. Overactivity of the subcallosal cingulate has been associated with failure of response to treatment in MDD, and it is a potential candidate for such a biomarker.

Methods

Investigators enrolled 82 patients with MDD currently not receiving treatment in a two-phase treatment study. Patients underwent a fluorodeoxyglucose positron emission tomography scan. After scanning, patient

SUBMITTER: McGrath CL 

PROVIDER: S-EPMC4063885 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature